This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Anti-Sm

Authoring team

Anti-Sm (Anti-Smith antibody)

This is antibody to a ribonuclear protein antigen.

It is associated with central nervous system involvement and nephritis in SLE. The HLA-markers associated with SLE and anti-dsDNA are HLA-DR2 and HLA-DQw6.

The Sm antigen represents not a single protein but a protein complex consisting of a group of core proteins (1)

  • at present, several proteins, being SmB1 (SmB), SmB2 (SmB’), SmB3 (SmN), SmD1, SmD2, SmD3, SmE, SmF and SmG, have been identified, which are expressed in the nuclei of all cells

Anti-sm antibodies are seen in less than 30% of SLE patients but have 99% specificity for SLE (2):

  • in SLE are usually always associated with Anti-U1-RNP antibodies, which are present in up to 30% of SLE patients

Notes:

  • the name Smith antigen is derived from a patient named Stephanie Smith, who was diagnosed with SLE in 1959
    • her physician dr. Tan, discovered a specific SLE antigen using the Ouchterlony agar diffusion method with her serum
    • this specific SLE antigen became known as the Smith antigen or Sm antigen

Reference:

  1. van Beers JJBC, Schreurs MWJ. Anti-Sm antibodies in the classification criteria of systemic lupus erythematosus. J Transl Autoimmun. 2022 Apr 13;5:100155.
  2. Justiz Vaillant AA, Goyal A, Varacallo MA. Systemic Lupus Erythematosus. 2023 Aug 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.